NCT05916963

Brief Summary

In view of the positive results of the numerous studies conducted on forced diuresis after extra-corporeal lithotripsy, the investigators chose to evaluate forced diuresis by injection of Furosemide associated with intravenous hydration, which has never before been the subject of a specific analysis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
374

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jan 2024

Geographic Reach
1 country

9 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 14, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 23, 2023

Completed
7 months until next milestone

Study Start

First participant enrolled

January 4, 2024

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 3, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 3, 2026

Completed
Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

2.2 years

First QC Date

June 14, 2023

Last Update Submit

November 18, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate of stone free patients

    Rate of stone-free patients 3 months after a flexible ureteroscopy for renal stone laser destruction, evaluated on the low dose abdomino-pelvic CT-Scan. A centralized review of the images will be performed by two specialized radiologists, in a blind and crossed way to allow a homogenization of the results

    At 3 months

Secondary Outcomes (4)

  • Rate of urinary infection

    From baseline to 30 days

  • Pain in a scale

    During the hospital stay

  • Opioid consumption

    During the hospital stay, an average of 1 day

  • Number of participants with adverse events

    From baseline to 3 months, an average of 1 day

Study Arms (2)

Furosemide

EXPERIMENTAL

Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.

Drug: Furosemide 40 mg

Usual care

NO INTERVENTION

Usual care, without injection of Furosemide.

Interventions

Injection of 40 mg of Furosemide during 10 minutes after the end of the flexible ureteroscopy for destruction of kidney stones with laser.

Furosemide

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients ≥ 18 years old and \< 80 years old
  • With the need to perform a flexible ureteroscopy with destruction of the kidney stones with laser
  • Participants covered by or entitled to social security
  • Written informed consent obtained from the participant
  • Ability for participant to comply with the requirements of the study

You may not qualify if:

  • Persons covered by articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, minors, and persons subject to a legal protection measure: guardianship or trusteeship)
  • Contra-indication to Furosemide:
  • Hyper-sensitivity to the active substance or one of the excipients
  • Hyper-sensitivity to Sulfonamide
  • Renal failure with oligo-anuria refractory to Furosemide
  • Hypokalemia \< 3,5 mmol/L
  • Severe hyponatremia
  • Hypovolemia with or without hypotension or dehydration
  • Ongoing hepatitis, hepatic insufficiency severe and hepatic encephalopathy
  • Patient having Furosemide as usual treatment
  • Patient requiring an injection of Aminoside or Vancomycin before or during the procedure
  • Participation in other interventional research with an investigational drug or medical device

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

CHU d'Angers

Angers, France

RECRUITING

Hospices Civils de Lyon

Lyon, France

RECRUITING

CHU de Nice

Nice, France

RECRUITING

CHU de Nîmes

Nîmes, France

RECRUITING

CHU de Rennes

Rennes, France

RECRUITING

CHU de Rouen

Rouen, France

RECRUITING

CHU de Toulouse

Toulouse, France

RECRUITING

Clinique La Croix du Sud

Toulouse, France

RECRUITING

CHRU de Tours

Tours, France

RECRUITING

Related Publications (1)

  • Letouche ML, Giraudeau B, Agier MS, Bruyere F. FIRE Stones: impact of forced diuresis on the residual fragment rate after flexible ureteroscopy for destruction of kidney stones with laser-protocol for a randomized controlled two-parallel group multicenter trial with blinding evaluation. Trials. 2024 Jul 4;25(1):455. doi: 10.1186/s13063-024-08309-0.

MeSH Terms

Conditions

Kidney Calculi

Interventions

Furosemide

Condition Hierarchy (Ancestors)

NephrolithiasisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrolithiasisUrinary CalculiMale Urogenital DiseasesCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

SulfanilamidesSulfonamidesAmidesOrganic ChemicalsAniline CompoundsAminesSulfonesSulfur Compounds

Central Study Contacts

Marie-Lou LETOUCHE, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The study will not be blinded except for the outcome assessment: radiologists in charge of interpreting CT-Scans will be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 14, 2023

First Posted

June 23, 2023

Study Start

January 4, 2024

Primary Completion

April 3, 2026

Study Completion

April 3, 2026

Last Updated

November 24, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations